Literature DB >> 31102172

Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells.

Aura D Herrera-Martínez1,2, Richard A Feelders1, Wouter W de Herder1, Justo P Castaño2, María Ángeles Gálvez Moreno2, Fadime Dogan1, Rosanna van Dungen1, Peter van Koetsveld1, Leo J Hofland3.   

Abstract

Prolonged remission of hypercortisolism with steroidogenesis inhibitors has been described in patients with ectopic adrenocorticotropic hormone (ACTH) syndrome. The anti-proliferative and pro-apoptotic effect of ketoconazole in human cancer cells was previously suggested. The aim of this study was to explore the effects of ketoconazole on ACTH-producing and non-ACTH-producing neuroendocrine tumor (NET) cell lines. The effects of ketoconazole alone, and in combination with somatostatin analogs, were evaluated in two human cell lines: DMS-79 (ectopic ACTH-producing small cell lung carcinoma) and BON-1 (human pancreatic NET). Total DNA measurement, apoptosis, cell cycle, chromogranin A (CgA)/proopiomelanocortin (POMC) expression by qRT-PCR, serotonin, CgA, and ACTH secretion assays were performed. In both cell lines, ketoconazole significantly suppressed cell growth and colony formation in a dose and time-dependent manner. The effect in DMS-79 was primarily cytotoxic, while it was more apoptotic in BON-1 cells. Ketoconazole also induced increase in G0/G1 phase in both cell lines and arrest in phase G2/M of BON-1 cells. Ketoconazole did not affect the secretion of serotonin, CgA, ACTH, or the mRNA expression of CgA and POMC. Decreased serotonin secretion was observed after the combination treatment with pasireotide. These results suggest a direct effect of ketoconazole on cell proliferation, apoptosis, and cell cycle in both ACTH- and non-ACTH-producing NET cells.

Entities:  

Keywords:  Combined therapy; Ketoconazole; Neuroendocrine tumors; Proliferation; Secretion

Year:  2019        PMID: 31102172     DOI: 10.1007/s12672-019-00361-6

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  57 in total

1.  Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes.

Authors:  Diego Ferone; Rosario Pivonello; P Martin Van Hagen; Virgil A S H Dalm; Elgin G R Lichtenauer-Kaligis; Marlijn Waaijers; Peter M Van Koetsveld; Diana M Mooy; Annamaria Colao; Francesco Minuto; Steven W J Lamberts; Leo J Hofland
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-11       Impact factor: 4.310

2.  A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.

Authors:  William D Figg; Sukyung Woo; Wenhui Zhu; Xiaohong Chen; A Seun Ajiboye; Seth M Steinberg; Douglas K Price; John J Wright; Howard L Parnes; Philip M Arlen; James L Gulley; William L Dahut
Journal:  J Urol       Date:  2010-06       Impact factor: 7.450

Review 3.  Ectopic adrenocorticotropic hormone syndrome.

Authors:  B L Wajchenberg; B B Mendonca; B Liberman; M A Pereira; P C Carneiro; A Wakamatsu; M A Kirschner
Journal:  Endocr Rev       Date:  1994-12       Impact factor: 19.871

4.  A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome.

Authors:  S W Lamberts; W W de Herder; E P Krenning; J C Reubi
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

5.  Chromogranin A expression in neoplastic cells affects tumor growth and morphogenesis in mouse models.

Authors:  Barbara Colombo; Flavio Curnis; Chiara Foglieni; Antonella Monno; Gianluigi Arrigoni; Angelo Corti
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

Review 6.  Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.

Authors:  M Fraenkel; M Kim; A Faggiano; W W de Herder; G D Valk
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

7.  The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.

Authors:  Joost van der Hoek; Aart-Jan van der Lelij; Richard A Feelders; Wouter W de Herder; Piet Uitterlinden; Kwai W Poon; Viktor Boerlin; Ian Lewis; Tillmann Krahnke; Leo J Hofland; Steven W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  2005-08       Impact factor: 3.478

8.  The ectopic adrenocorticotropic hormone syndrome in carcinoid tumors.

Authors:  Poorya Fazel; Prasanthi Ganesa; Robert G Mennel; Ned A Austin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-04

9.  Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.

Authors:  Annarita Ianniello; Maddalena Sansovini; Stefano Severi; Silvia Nicolini; Chiara Maria Grana; Katrin Massri; Alberto Bongiovanni; Lorenzo Antonuzzo; Valentina Di Iorio; Anna Sarnelli; Paola Caroli; Manuela Monti; Emanuela Scarpi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-27       Impact factor: 9.236

Review 10.  Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use.

Authors:  J H Van Tyle
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

View more
  6 in total

Review 1.  Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer.

Authors:  Carlo Ganini; Ivano Amelio; Riccardo Bertolo; Eleonora Candi; Angela Cappello; Chiara Cipriani; Alessandro Mauriello; Carla Marani; Gerry Melino; Manuela Montanaro; Maria Emanuela Natale; Giuseppe Tisone; Yufang Shi; Ying Wang; Pierluigi Bove
Journal:  Discov Oncol       Date:  2021-10-27

2.  Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway.

Authors:  Xudong Liu; Jie Gao; Yaohui Sun; Feng Zhang; Wenzhi Guo; Shuijun Zhang
Journal:  Drug Des Devel Ther       Date:  2022-03-29       Impact factor: 4.162

3.  Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.

Authors:  Omar Prado-Carrillo; Abner Arenas-Ramírez; Monserrat Llaguno-Munive; Rafael Jurado; Jazmin Pérez-Rojas; Eduardo Cervera-Ceballos; Patricia Garcia-Lopez
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

4.  Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.

Authors:  Amber Blaauboer; Stephanie Booy; Peter M van Koetsveld; Bas Karels; Fadime Dogan; Suzanne van Zwienen; Casper H J van Eijck; Leo J Hofland
Journal:  BMC Cancer       Date:  2020-09-23       Impact factor: 4.430

5.  Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors.

Authors:  Sergio Pedraza-Arevalo; Alejandro Ibáñez-Costa; Ricardo Blázquez-Encinas; Miguel R Branco; Mari C Vázquez-Borrego; Aura D Herrera-Martínez; Eva Venegas-Moreno; Raquel Serrano-Blanch; Álvaro Arjona-Sánchez; María A Gálvez-Moreno; Marta Korbonits; Alfonso Soto-Moreno; Manuel D Gahete; Marika Charalambous; Raúl M Luque; Justo P Castaño
Journal:  Mol Oncol       Date:  2021-10-26       Impact factor: 6.603

6.  The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation.

Authors:  Amber Blaauboer; Peter M van Koetsveld; Dana A M Mustafa; Jasper Dumas; Fadime Dogan; Suzanne van Zwienen; Casper H J van Eijck; Leo J Hofland
Journal:  Biomedicines       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.